Literature DB >> 23765596

Common chromosomal fragile site FRA16D tumor suppressor WWOX gene expression and metabolic reprograming in cells.

Sonia Dayan1, Louise V O'Keefe, Amanda Choo, Robert I Richards.   

Abstract

The WWOX gene spans the FRA16D common chromosomal fragile site and is able to suppress tumor growth. FRA16D is a frequent site of DNA instability in cancer resulting in reduced levels of WWOX expression. Altered levels of WWOX have been shown to affect metabolism. Whereas metabolic reprograming of cells from oxidative phosphorylation to aerobic glycolysis is a major hallmark of tumors, the relationship between common chromosomal fragile site genes and altered metabolism has been unclear. Here we report that altering metabolism from glycolysis to oxidative phosphorylation causes stable increase in steady-state levels of transcripts of the WWOX gene. Consistent with this, exposure to hypoxic conditions, in which cells rely on glycolysis, causes a downregulation of WWOX mRNA. The function of WWOX is therefore intimately integrated with metabolism, as WWOX not only contributes to the metabolic state of cells, its transcript levels are also linked to intracellular metabolic state.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23765596     DOI: 10.1002/gcc.22078

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  17 in total

Review 1.  WWOX, the chromosomal fragile site FRA16D spanning gene: its role in metabolism and contribution to cancer.

Authors:  Robert I Richards; Amanda Choo; Cheng Shoou Lee; Sonia Dayan; Louise O'Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2015-01-16

2.  Tumor suppressor WWOX regulates glucose metabolism via HIF1α modulation.

Authors:  M Abu-Remaileh; R I Aqeilan
Journal:  Cell Death Differ       Date:  2014-07-11       Impact factor: 15.828

Review 3.  The common fragile site FRA16D gene product WWOX: roles in tumor suppression and genomic stability.

Authors:  Rami I Aqeilan; Muhannad Abu-Remaileh; Mohammad Abu-Odeh
Journal:  Cell Mol Life Sci       Date:  2014-09-23       Impact factor: 9.261

4.  Early infantile-onset epileptic encephalopathy 28 due to a homozygous microdeletion involving the WWOX gene in a region of uniparental disomy.

Authors:  Mariska Davids; Thomas Markello; Lynne A Wolfe; Xenia Chepa-Lotrea; Cynthia J Tifft; William A Gahl; May Christine V Malicdan
Journal:  Hum Mutat       Date:  2018-11-18       Impact factor: 4.878

Review 5.  Pleiotropic Functions of Tumor Suppressor WWOX in Normal and Cancer Cells.

Authors:  Muhannad Abu-Remaileh; Emma Joy-Dodson; Ora Schueler-Furman; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2015-10-23       Impact factor: 5.157

Review 6.  WW domain-containing oxidoreductase in neuronal injury and neurological diseases.

Authors:  Hsin-Tzu Chang; Chan-Chuan Liu; Shur-Tzu Chen; Ye Vone Yap; Nan-Shang Chang; Chun-I Sze
Journal:  Oncotarget       Date:  2014-12-15

7.  The supposed tumor suppressor gene WWOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration.

Authors:  Ghada Abdel-Salam; Michaela Thoenes; Hanan H Afifi; Friederike Körber; Daniel Swan; Hanno Jörn Bolz
Journal:  Orphanet J Rare Dis       Date:  2014-01-23       Impact factor: 4.123

8.  Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples.

Authors:  Jean-Pierre Issa; Razelle Kurzrock; Ignacio I Wistuba; David J Stewart; Maria I Nunez; Jaroslav Jelinek; David Hong; Sanjay Gupta; Marcelo Aldaz
Journal:  Clin Epigenetics       Date:  2014-07-03       Impact factor: 6.551

Review 9.  The tumor suppressor WW domain-containing oxidoreductase modulates cell metabolism.

Authors:  Muhannad Abu-Remaileh; Rami I Aqeilan
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-08

10.  Tumor Suppressor WWOX Contributes to the Elimination of Tumorigenic Cells in Drosophila melanogaster.

Authors:  Louise V O'Keefe; Cheng Shoou Lee; Amanda Choo; Robert I Richards
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.